Amgen teases 'promising' phase 2 data for closely watched KRAS prospect

Just two weeks after unveiling full data from its phase 1 program, Amgen’s KRAS inhibitor is back with more. The Big Biotech teased results from a phase 2 study that it says echo the efficacy seen in its closely watched phase 1 trial.

While the earlier study tested four dose levels of the drug, sotorasib, the phase 2 study tested the top dose of the drug in 129 patients with non-small cell lung cancer (NSCLC) whose disease had worsened despite trying a median of two other treatments. Amgen kept specifics under wraps but said Monday afternoon that the new data were “consistent” with the 35% response rate seen in 34 patients who received the top dose in the earlier trial.